Homozygous Familial Hypercholesterolemia - Epidemiology Forecast - 2036

Homozygous Familial Hypercholesterolemia (HoFH) Insights and Trends

• According to DelveInsight's analysis, the total prevalent cases of HoFH in 7MM were found to be approximately 1,840 in 2025 and are estimated to rise with a significant CAGR throughout the study period.
• The United States accounted for the maximum number of diagnosed prevalent cases of HoFH which was estimated to be around 900 in 2025 and are anticipated to increase by a significant CAGR.
• As per DelveInsight's analysis, the US alone accounted for about 50% of the total diagnosed prevalent cases of HoFH in 2025 among the 7MM.
• Assessments as per DelveInsight's analysts showed that Germany accounted for the highest total diagnosed prevalent cases of HoFH in 2024 among EU4 and the UK and these cases are further expected to decrease during the forecasted period (2022-2036).
• HoFH was historically estimated to affect about 1 in 1,000,000 individuals in the general population. However, more recent molecular and genetic epidemiology studies indicate that the condition may be more common than previously thought, with revised estimates ranging from approximately 1 in 160,000 to 1 in 300,000 based on secondary data analyses.

DelveInsight's 'Homozygous Familial Hypercholesterolemia (HoFH)- Epidemiology Forecast - 2036' report delivers an in-depth understanding of the HoFH, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Homozygous Familial Hypercholesterolemia (HoFH) Understanding and Diagnosis Algorithm

Homozygous Familial Hypercholesterolemia Overview

HoFH is a rare, inherited genetic disorder characterized by extremely high levels of low-density lipoprotein cholesterol (LDL-C) from birth, leading to early-onset and aggressive atherosclerotic cardiovascular disease. It is caused by mutations in genes involved in LDL metabolism, most commonly the LDL receptor (LDLR), apolipoprotein B (APOB), or PCSK9, resulting in severely impaired clearance of LDL cholesterol from the bloodstream. Unlike heterozygous familial hypercholesterolemia, HoFH occurs when defective genes are inherited from both parents, making the condition significantly more severe. Clinically, patients often present with cutaneous or tendon xanthomas in childhood, corneal arcus, and premature cardiovascular complications, sometimes developing as early as adolescence. Despite its rarity, HoFH carries a significant burden due to high morbidity, early mortality, and the need for lifelong intensive treatment, emphasizing the importance of early identification and management.

Homozygous Familial Hypercholesterolemia Diagnosis

The diagnosis of HoFH involves a combination of clinical assessment, lipid profiling, and genetic testing. Patients typically exhibit markedly elevated LDL-C levels (often >500 mg/dL if untreated), which is a key diagnostic feature. A family history of hypercholesterolemia or premature cardiovascular disease further supports the diagnosis. Physical signs such as xanthomas can provide early clinical clues. Genetic testing is considered the gold standard for confirming mutations in LDLR, APOB, or PCSK9 genes and helps differentiate HoFH from other lipid disorders. Additionally, imaging techniques such as coronary artery calcium scoring or carotid ultrasound may be used to evaluate the extent of cardiovascular involvement. Early and accurate diagnosis is critical for initiating aggressive lipid-lowering therapy and reducing the risk of severe cardiovascular events.

Homozygous Familial Hypercholesterolemia Epidemiology

Key Findings from Homozygous Familial Hypercholesterolemia Epidemiological Analysis and Forecast

• According to DelveInsight's estimates, the total diagnosed prevalent cases of HoFH in the 7MM were approximately 1,840 in 2025.
• According to estimates based on DelveInsight's epidemiology model, the total diagnosed prevalent cases of HoFH in the US were estimated to be approximately ~870 in 2025.
• Among the 7MM, the EU4 and the UK accounted for approximately 40% of the total diagnosed prevalent cases of HoFH in 2025, which is expected to increase further during the study period.
• According to DelveInsight's analysis in the US, nearly 80% of cases were reported due to mutation in the LDLR gene.
• Assessments as per DelveInsight's analysts showed that Germany accounted for the highest total diagnosed prevalent cases of HoFH in 2025 among EU4 and the UK.

Scope of the Report:

• The report covers a segment of an executive summary, a descriptive overview of Homozygous Familial Hypercholesterolemia (HoFH), explaining its causes, signs and symptoms, and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

Report Insights

Homozygous Familial Hypercholesterolemia (HoFH) Patient Population Forecast

Report Key Strengths

• Epidemiology-based (epi-based) Bottom-up Forecasting
• 11-year Forecast
• Patient Burden Trends (by geography)

FAQs:

• What are the disease risks, burdens, and unmet needs of Homozygous Familial Hypercholesterolemia (HoFH)? What will be the growth opportunities across the 7MM concerning the patient population with homozygous familial hypercholesterolemia?
• What is the historical and forecasted Homozygous Familial Hypercholesterolemia (HoFH) patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy:

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand key opinion leaders' perspectives around the diagnostic challenges to overcome barriers in the future.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.